Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention

Health Canada carried out a safety review to look into the use of atypical antipsychotics and the potential risk of having difficulty urinating or not being able to fully empty the bladder (urinary retention). This can be an emergency that requires medical attention. This review was triggered by new safety information received from the manufacturer of Seroquel (quetiapine) that included reports of urinary retention in patients using quetiapine.

Data and Resources

Additional Info

Field	Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French)	Résumé de l’examen de l'innocuité - Antipsychotiques atypiques – Évaluation du risque potentiel de rétention d’urine
Update Frequency	as_needed
Geographic Scope	[]
Criticality Level	[]
Sensitivity Level	unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published	2020-12-07 00:00:00
Open Canada Date Modified
Open Canada Subject	["health_and_safety"]
Open Canada Keywords	{"fr": ["Examen sommaire de l'innocuité", "antipsychotiques atypiques", "évaluation", "risque potentiel", "rétention urinaire", "difficulté à uriner", "nouvelles informations sur l'innocuité", "fabricant", "Seroquel (quétiapine)"], "en": ["Summary Safety Review", "atypical antipsychotics", "assessing", "potential risk", "Urinary Retention", "difficulty urinating", "new safety information", "manufacturer", "Seroquel (quetiapine)"]}
Open Canada Collection	publication
Principal Organization
Reference Data
Official Source